110178-74-0

Basic information

• Product Name: 4-(5-METHYL-1 H-BENZOIMIDAZOL-2-YL)-PHENYLAMINE
• Synonyms: 4-(5-METHYL-1 H-BENZOIMIDAZOL-2-YL)-PHENYLAMINE;4-(5-methyl-1H-benzimidazol-2-yl)aniline;[4-(6-methyl-1H-benzimidazol-2-yl)phenyl]amine;4-(6-methyl-1H-benzimidazol-2-yl)aniline;4-(5-methyl-1H-benzo[d]imidazol-2-yl)aniline
• CAS NO: 110178-74-0
• Molecular Formula: C₁₄H₁₃N₃
• Molecular Weight: 223.27
• Mol File: 110178-74-0.mol

Chemical Properties

• Boiling Point: 474.8°C at 760 mmHg
• Flash Point: 272.4°C
• Appearance: /
• Density: 1.247g/cm³
• Vapor Pressure: 3.5E-09mmHg at 25°C
• Refractive Index: 1.714
• PKA: 11.80±0.10(Predicted)
• CAS DataBase Reference: 4-(5-METHYL-1 H-BENZOIMIDAZOL-2-YL)-PHENYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(5-METHYL-1 H-BENZOIMIDAZOL-2-YL)-PHENYLAMINE(110178-74-0)
• EPA Substance Registry System: 4-(5-METHYL-1 H-BENZOIMIDAZOL-2-YL)-PHENYLAMINE(110178-74-0)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 110178-74-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C14H13N3/c1-9-2-7-12-13(8-9)17-14(16-12)10-3-5-11(15)6-4-10/h2-8H,15H2,1H3,(H,16,17)

Upstream product

• 733753-70-3 1-nitrobenzimidazole 
• 150-13-0 4-amino-benzoic acid 
• 496-72-0 4-methyl-1,2-diaminobenzene 
• 555-16-8 4-nitrobenzaldehdye 
• 69570-93-0 5‐methyl‐2‐(4‐nitrophenyl)‐1H‐benzo[d]imidazole 
• 62-23-7 4-nitro-benzoic acid 
• 106-49-0 p-toluidine 
• 6917-08-4 N-(4-methylphenyl)-4-nitrobenzamide 
• 303098-88-6 N-(4-methyl-2-nitrophenyl)-4-nitrobenzamide 

Downstream Products

• 1095340-69-4 N-(4-(6-methyl-1H-benzo[d]imidazol-2-yl)phenyl)-1-(thiophen-2-ylsulfonyl)piperidine-4-carboxamide 

Relevant articles and documents

Benzimidazole based mesogenic Schiff-bases: Synthesis and characterization

Two homologous series of mesogenic Schiff-bases, N-4-((alkoxy)-(phenyl-3-hydroxy-4-(4-(5-methylbenzimidazol))-2-alkoxysalicylaldimine)benzoate (7a–d) and N-4′-(5-methyl-benzimidazole)-phenyl-4-alkoxysalicylaldimine (8a–d) incorporating benzimidazole moiety have been prepared and the molecular structures studied by FT-IR, NMR and ESI-MS spectrometry. Mesogenic behaviour was investigated by polarizing optical microscopy (POM), differential scanning calorimetry (DSC) and variable temperature powder X-ray diffraction (PXRD) techniques. Changing the spacer (ester-linked to non-ester linked) of the Schiff-base results in enhancement of thermal stability and phase transition temperature. The members of series-I show monotropic SmA while those of series-II reflect enantiotropic SmA mesomorphism. An electrochemical study of a representative Schiff base in each series (7d and 8c) showed an electrical band gap 1.26?eV and 1.22?eV respectively.

1-[4-(1H-Benzoimidazol-2-yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl] -urea derivatives as small molecule heparanase inhibitors

A novel class of 1-[4-(1H-benzoimidazol-2-yl)-phenyl]-3-[4-(1H- benzoimidazol-2-yl)-phenyl]-ureas are described as potent inhibitors of heparanase. Among them are 1,3-bis-[4-(1H-benzoimidazol-2-yl)-phenyl]-urea (7a) and 1,3-bis-[4-(5,6-dimethyl-1H-benzoimidazol-2-yl)-phenyl]-urea (7d), which displayed good heparanase inhibitory activity (IC50 0.075-0.27 μM). Compound 7a showed good efficacy in a B16 metastasis model.

Benzimidazole compounds for regulating IgE

This invention relates to a family of phenylbenzimidazole analogs, which are inhibitors of the IgE response to allergens. These compounds are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.

Benzimidazole derivatives as modulators of IgE

This invention relates to a family of benzimidazole analogs, which are inhibitors of the IgF response to allergens. These compounds are useful in the treatment of allergy, asthma, or any diseases where IgE is pathogenic.

Benzimidazole compounds for regulating IgE

This invention relates to a family of phenylbenzimidazole analogs, which are inhibitors of the IgE response to allergens. These compounds are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.

Benzimidazole derivatives as modulators of IgE

This invention relates to a family of diacyl benzimidazole analogs, which are inhibitors of the IgE response to allergens. These compounds are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.